Cetera Investment Advisers
BEAM icon

Cetera Investment Advisers’s Beam Therapeutics BEAM Stock Holding History

Cetera Investment Advisers’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,634
Closed -$239K – 4814
2025
Q4 		$239K Buy
+8,634
New +$220K ﹤0.01% 4104

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Cetera Investment Advisers's BEAM Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 8,634 shares — an estimated $239K sold.

Cetera Investment Advisers first reported a position in BEAM in Q4 2025 and held it in 1 quarter. The position peaked at $239K in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 8,634 Beam Therapeutics shares in Q1 2026, an estimated $239K.
  • Cetera Investment Advisers first reported a position in Beam Therapeutics in Q4 2025 and held it in 1 quarter.
  • Cetera Investment Advisers's Beam Therapeutics position peaked at $239K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.